+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 5206757
  • Drug Pipelines
  • December 2020
  • Region: Global
  • 131 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AB2 Bio Ltd
  • Cerecor
  • Novartis
  • Roche
  • Swedish Orphan Biovitrum
  • MORE
The “Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the market trends of adult-onset Still's disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The adult-onset Still's disease (AOSD) market report provides analysis regarding current treatment practices, emerging drug-like CERC-007 (Cerecor) and potential therapies, market share of the individual therapies, historical, current, and forecasted adult-onset Still's disease market size from 2017 to 2030, segmented by seven major markets.

The report also covers current adult-onset Still's disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Adult-onset Still's Disease- Disease Understanding and Treatment Algorithm

Adult-onset Still's Disease Overview

Adult-onset Still's Disease (AOSD) is a rare type of arthritis thought to be autoimmune or autoinflammatory. It has similar symptoms to systemic-onset juvenile idiopathic arthritis - fever, rash, and joint pain. It begins in adulthood, so it is compared to rheumatoid arthritis. Inflammation may affect a few joints at first. Over time, more joints may be involved. Some people may have only one bout of the illness followed by lasting remission (no visible symptoms), while others develop chronic arthritis.

In adult-onset Still's disease, symptoms typically come and go in episodes. For some, these go on for about a year, and then the disease goes away. For others, the episodes come on at random, going away for weeks or months and then coming back. The patient may also have chronic AOSD, where the symptoms are more constant than others. The initial indications are high fever and pink rash.

Diagnosing AOSD is difficult because there are no specific tests or distinguishing laboratory (histopathologic) findings that differentiate the disorder from similar disorders. A diagnosis of AOSD is usually made based upon thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and the exclusion of other possible disorders (diagnosis of exclusion). A variety of tests may be performed to aid in the diagnosis, including blood tests and x-ray studies that reveal changes in the bones or joints or enlargement of the spleen or liver. An echocardiogram, which uses sound waves to create a picture of the heart, may reveal inflammation of the pericardium or myocardium.

Adult-onset Still's Disease Treatment

This chapter covers the details of conventional and current medical therapies available in the adult-onset Still's disease market to treat the condition. It also provides the country-wise adult-onset Still's disease treatment guidelines across the United States, Europe, and Japan.

The adult-onset Still's disease market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides adult-onset Still's disease treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Currently, the treatment of AOSD patients remains empirical. The disease's clinical course is variable and ranges from self-limiting clinical forms to life-threatening complications; thus, the best therapy has not yet been defined and still counts on personal clinical experiences. The ongoing predominant clinical features (systemic or articular) and the presence/absence of complications must be considered to identify the appropriate individualized strategy factors determining the disease phase (onset, maintenance, flares).

The treatment of AOSD is centered on nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, and antirheumatic agents.

Adult-onset Still's Disease Epidemiology

The adult-onset Still's disease epidemiology chapters provide insights about historical and current adult-onset Still's disease patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Adult-onset Still's Disease epidemiology is segmented by total prevalent cases, gender-specific cases, and complications-associated with AOSD. The report includes a thorough analysis of all segmentations.

According to the publisher's estimate, the total prevalent cases of adult-onset Still's disease in the 7MM countries was 13,191 in 2017. As per the estimates, the United States had the highest prevalent population of adult-onset Still's disease with 3,970 cases in 2017

Adult-onset Still's Disease Drug Chapters

The drug chapter segment of the Adult-onset Still's Disease report encloses the detailed analysis of Adult-onset Still's Disease pipeline drug. It also helps understand the Adult-onset Still's Disease clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.

To date, the use of medications in adult-onset Still's disease has been considered controversial. Many treatments discussed in this section remain investigational. Canakinumab (INN), sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including AOSD. It is a human monoclonal antibody targeted at interleukin-1 beta and has no cross-reactivity with other interleukin-1 family members, including interleukin-1 alpha. Ilaris works by blocking the action of IL-1 beta for a sustained period, therefore inhibiting inflammation caused by its over-production. Apart from these, many drugs are still under trials or need more proper studies to prove efficacy. Thus, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during the forecast period.

Adult-onset Still's Disease Market Outlook

The adult-onset Still's disease market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest adult-onset Still's disease market size, with USD 14.3 million, while Japan's AOSD market size was USD 8.5 million in 2017.

Adult-onset Still's Disease Drugs Uptake

This section focuses on the uptake of the potential drugs in the adult-onset Still's disease market expected to get launched in the market during the study period 2017-2030. The analysis covers adult-onset Still's disease market uptake by drugs, patient uptake by therapies, and drug sale.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the adult-onset Still's disease market is anticipated to experience a positive shift in the coming years due to the expected launch of emerging therapies.

Adult-onset Still's Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses adult-onset Still's disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers adult-onset Still's disease collaborations, acquisition and merger, licensing, patent details, and other information for Adult-onset Still's Disease emerging therapies.

Reimbursement Scenario in Alcoholic Hepatitis

Proactively approaching reimbursement can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Adult-onset Still's Disease domain through primary research to fill the data gaps and validate the secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Adult-onset Still's Disease Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights
  • In the coming years, the Adult-onset Still's Disease market scenario is expected to alter across the 7MM due to the launch of a few therapies covering the drawbacks of the standard of care.
  • The in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Adult-onset Still's Disease Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Adult-onset Still's Disease Pipeline Analysis
  • Adult-onset Still's Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Adult-onset Still's Disease Report Key Strengths
  • 11-years Forecast
  • 7MM Coverage
  • Adult-onset Still's Disease Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake
Adult-onset Still's Disease Report Assessment
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the adult-onset Still's disease market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the adult-onset Still's disease total market size and market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest adult-onset Still's disease market size during the forecast period (2017-2030)?
  • At what CAGR, adult-onset Still's disease market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the adult-onset Still's disease market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the adult-onset Still's disease market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risks, burdens, and unmet needs of adult-onset Still's disease?
  • What is the historical adult-onset Still's disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of adult-onset Still's disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to adult-onset Still's disease?
  • Out of all 7MM countries, which country would have the highest prevalent population of adult-onset Still's disease during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for adult-onset Still's disease treatment, along with the approved therapy?
  • What are the current treatment guidelines for treating adult-onset Still's disease in the USA, Europe, and Japan?
  • What is the adult-onset Still's disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of adult-onset Still's disease?
  • How many therapies are developed by each company for adult-onset Still's disease treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for adult-onset Still's disease treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the adult-onset Still's disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for adult-onset Still's disease and their status?
  • What are the key designations that have been granted for the emerging therapies for adult-onset Still's disease?
  • What are the global historical and forecasted market of adult-onset Still's disease?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the adult-onset Still's disease market
  • To understand the future market competition in the adult-onset Still's disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for adult-onset Still's disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the adult-onset Still's disease market
  • To understand the future market competition in the adult-onset Still's disease market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AB2 Bio Ltd
  • Cerecor
  • Novartis
  • Roche
  • Swedish Orphan Biovitrum
  • MORE
1 Key Insights

2 Executive Summary of AOSD

3 Adult-onset Still’s Disease Market Overview at a Glance
3.1 Market Share (%) Distribution of Adult-onset Still’s Disease in 2017
3.2 Market Share (%) Distribution of Adult-onset Still’s Disease in 2030

4 Overview and Background
4.1 Introduction
4.2 Etiology
4.3 History and Physical
4.4 Symptoms
4.5 Pathogenesis
4.6 Clinical Manifestation
4.7 AOSD biomarkers
4.8 Diagnosis
4.8.1 Diagnostic criteria for AOSD

5 Epidemiology and Patient Population
5.1 Key Findings

6 7MM Epidemiology
6.1 Assumptions and rationale
6.2 Total Prevalent Cases of Adult-onset Still’s Disease (AOSD) in 7MM
6.3 The United States
6.3.1 Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the United States
6.3.2 Gender-Specific cases of Adult-onset Still’s Disease (AOSD) in the United States
6.3.3 Complications Associated with Adult-onset Still’s Disease (AOSD) in the United States
6.4 EU5 Countries
6.4.1 Germany
6.4.2 France
6.4.3 Italy
6.4.4 Spain
6.4.5 United Kingdom
6.5 Japan

7 Treatment

8 Unmet Needs

9 Organizations contributing toward AOSD

10 Case Study
10.1 Adult-onset Still’s disease initially thought to be an odontogenic infection: A case report
10.2 Adult-onset Still’s Disease Complicated by Autoimmune Hepatitis: Successful Treatment with Infliximab
10.3 Complex presentation of adult-onset Still’s disease
10.4 A complete response to steroids in dural inflammatory pseudotumor associated with Still’s disease

11 KOL Views

12 Patient Journey

13 Marketed Therapies
13.1 Canakinumab: Novartis
13.1.1 Drug Description
13.1.2 Other Development Activities
13.1.3 Clinical Development
13.1.4 Safety and Efficacy
13.2 Anakinra: Swedish Orphan Biovitrum
13.2.1 Drug Description
13.2.2 Other Development Activities
13.2.3 Clinical Development
13.2.4 Safety and Efficacy
13.3 Tocilizumab: Roche
13.3.1 Drug Description
13.3.2 Other Development Activities
13.3.3 Clinical Development
13.3.4 Safety and Efficacy

14 Emerging Therapies
14.1 CERC-007: Cerecor
14.1.1 Drug Description
14.1.2 Other Development Activities
14.1.3 Safety and Efficacy

15 Other Promising Therapies
15.1 Tadekinig Alfa: AB2 Bio Ltd
15.1.1 Drug Description
15.1.2 Other Development Activities
15.1.3 Clinical Development
15.1.4 Safety and Efficacy

16 Adult-onset Still’s Disease (AOSD): 7 Major Market Analysis
16.1 Key Findings
16.2 Market Size of Adult-onset Still’s Disease (AOSD) in 7MM

17 Seven Major Market Outlook
17.1 The United States Market Size
17.1.1 Total Market Size of Adult-onset Still’s Disease (AOSD) in the United States
17.1.2 Total Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in the United States
17.2 Germany
17.2.1 The total market size of Adult-onset Still’s Disease (AOSD) in Germany
17.2.2 Market size of Adult-onset Still’s Disease (AOSD) by Therapies in Germany
17.3 France
17.3.1 The total market size of Adult-onset Still’s Disease (AOSD) in France
17.3.2 Market size of Adult-onset Still’s Disease (AOSD) by Therapies in France
17.4 Italy
17.4.1 The total market size of Adult-onset Still’s Disease (AOSD) in Italy
17.4.2 Market size of Adult-onset Still’s Disease (AOSD) by Therapies in Italy
17.5 Spain
17.5.1 Total Market Size of Adult-onset Still’s Disease (AOSD) in Spain
17.5.2 Market size of Adult-onset Still’s Disease (AOSD) by Therapies in Spain
17.6 United Kingdom
17.6.1 The total market size of Adult-onset Still’s Disease (AOSD) in the United Kingdom
17.6.2 Market size of Adult-onset Still’s Disease (AOSD) by Therapies in the UK
17.7 Japan
17.7.1 The total market size of Adult-onset Still’s Disease (AOSD) in Japan
17.7.2 Market size of Adult-onset Still’s Disease (AOSD) by Therapies in Japan

18 Market Drivers

19 Market Barriers

20 SWOT Analysis for AOSD

21 Reimbursement

22 Appendix
22.1 Report Methodology
22.2 References

23 Publisher Capabilities

24 Disclaimer

25 About the Publisher

List of Tables
Table 1: Summary of Adult-onset Still’s Disease Market, Epidemiology, and Key Events (2017-2030)
Table 2: Serum biomarkers in AOSD
Table 3: Total Prevalent Cases of Adult-onset Still’s Disease (AOSD) in 7MM (2017-2030)
Table 4: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the United States (2017-2030)
Table 5: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Table 6: Complications Associated with Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Table 7: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Table 8: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Table 9: Complications Associated with Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Table 10: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Table 11: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Table 12: Complications Associated with Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Table 13: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Table 14: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Table 15: Complications Associated with Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Table 16: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Table 17: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Table 18: Complications Associated with Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Table 19: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the United Kingdom (2017-2030)
Table 20: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Table 21: Complications Associated with Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Table 22: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Table 23: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Table 24: Complications Associated with Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Table 25: Canakinumab, Product Description
Table 26: Canakinumab, Clinical Trial Description, 2020
Table 27: Anakinra, Product Description
Table 28: Anakinra, Clinical Trial Description, 2020
Table 29: Tocilizumab, Product Description
Table 30: Tocilizumab, Clinical Trial Description, 2020
Table 31: CERC-007, Product Description
Table 32: Tadekinig Alfa, Product Description
Table 33: Tadekinig Alfa, Clinical Trial Description, 2020
Table 34: Market Size of Adult-onset Still’s Disease (AOSD) in 7MM in USD Million (2017-2030)
Table 35: The US Market Size of Adult-onset Still’s Disease (AOSD) in USD Million (2017-2030)
Table 36: US Market Size of Adult-onset Still’s Disease (AOSD) in USD Million (2017-2030)
Table 37: Market Size of Adult-onset Still’s Disease (AOSD) in Germany, USD Millions (2017-2030)
Table 38: Germany Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in USD Million (2017-2030)
Table 39: Market Size of Adult-onset Still’s Disease (AOSD) associated in France, USD Millions (2017-2030)
Table 40: France Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in USD Million (2017-2030)
Table 41: Market Size of Adult-onset Still’s Disease (AOSD) in Italy, USD Millions (2017-2030)
Table 42: Italy Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in USD Million (2017-2030)
Table 43: Market Size of Adult-onset Still’s Disease (AOSD) in Spain, USD Millions (2017-2030)
Table 44: Spain Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in USD Million (2017-2030)
Table 45: Market Size of Adult-onset Still’s Disease (AOSD) in the UK, USD Millions (2017-2030)
Table 46: UK Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in USD Million (2017-2030)
Table 47: Market Size of Adult-onset Still’s Disease (AOSD) in Japan, USD Millions (2017-2030)
Table 48: Japan Market Size of Adult-onset Still’s Disease (AOSD) by Therapies in USD Million (2017-2030)

List of Figures
Figure 1: Pathogenesis
Figure 2: Total Prevalent Cases of Adult-onset Still’s Disease (AOSD) in 7MM (2017-2030)
Figure 3: Total Prevalent Cases of AOSD in the United States (2017-2030)
Figure 4: Gender-Specific cases of Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Figure 5: Complications Associated with Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Figure 6: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Figure 7: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Figure 8: Complications Associated with Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Figure 9: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Figure 10: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Figure 11: Complications Associated with Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Figure 12: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Figure 13: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Figure 14: Complications Associated with Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Figure 15: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Figure 16: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Figure 17: Complications Associated with Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Figure 18: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Figure 19: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Figure 20: Complications Associated with Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Figure 21: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Figure 22: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Figure 23: Complications Associated with Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Figure 24: Treatment Algorithm of Adult-onset Still’s Disease
Figure 25: Unmet Needs of Adult-onset Still’s Disease
Figure 26: Market Size of Adult-onset Still’s Disease (AOSD) in USD Million (2017-2030)
Figure 27: Market Size of Adult-onset Still’s Disease (AOSD) in the US, USD Millions (2017-2030)
Figure 28: Market Size of Adult-onset Still’s Disease (AOSD) in the US by therapies, USD Millions (2017-2030)
Figure 29: Market Size of Adult-onset Still’s Disease (AOSD) in Germany, USD Millions (2017-2030)
Figure 30: Market Size of Adult-onset Still’s Disease (AOSD) in Germany by therapies, USD Millions (2017-2030)
Figure 31: Market Size of Adult-onset Still’s Disease (AOSD) in France, USD Millions (2017-2030)
Figure 32: Market Size of Adult-onset Still’s Disease (AOSD) in France by therapies, USD Millions (2017-2030)
Figure 33: Market Size of Adult-onset Still’s Disease (AOSD) in Italy, USD Millions (2017-2030)
Figure 34: Market Size of Adult-onset Still’s Disease (AOSD) in Italy by therapies, USD Millions (2017-2030)
Figure 35: Market Size of Adult-onset Still’s Disease (AOSD) in Spain, USD Millions (2017-2030)
Figure 36: Market Size of Adult-onset Still’s Disease (AOSD) in Spain by therapies, USD Millions (2017-2030)
Figure 37: Market Size of Adult-onset Still’s Disease (AOSD) in the UK, USD Millions (2017-2030)
Figure 38: Market Size of Adult-onset Still’s Disease (AOSD) in the UK by therapies, USD Millions (2017-2030)
Figure 39: Market Size of Adult-onset Still’s Disease (AOSD) in Japan, USD Millions (2017-2030)
Figure 40: Market Size of Adult-onset Still’s Disease (AOSD) in Japan by therapies, USD Millions (2017-2030)
Figure 41: Market Drivers
Figure 42: Market Barriers
Note: Product cover images may vary from those shown
3 of 3
  • Novartis
  • Swedish Orphan Biovitrum
  • Roche
  • Cerecor
  • AB2 Bio Ltd
Note: Product cover images may vary from those shown
Adroll
adroll